Community randomised controlled trial to assess the impact of vaccination with a pneumococcal conjugate vaccine on nasopharyngeal carriage of pneumococci in the Gambia

Conditions

Pneumococcal infection or colonisation Infections and Infestations Pneumococcal infection

Bojang A, Kendall L, Usuf E, Egere U, Mulwa S, Antonio M, Greenwood B, Hill PC, Roca A.

2017-08-257 citations

Nasopharyngeal Carriage of Pneumococci Four Years after Community-Wide Vaccination with PCV-7 in The Gambia: Long-Term Evaluation of a Cluster Randomized Trial

Anna Roca, Michel Dione, Abdoulie Bojang, John Townend, Uzochukwu Egere et al. (11 authors)

PLoS ONE2013-09-2728 citations

10.1371/journal.pone.0072198

Pneumococcal antibody concentrations of subjects in communities fully or partially vaccinated with a seven-valent pneumococcal conjugate vaccine.

Ota MO, Roca A, Bottomley C, Hill PC, Egere U, Greenwood B, Adegbola RA.

2012-08-143 citations

10.1371/journal.pone.0042997

Effect of age and vaccination with a pneumococcal conjugate vaccine on the density of pneumococcal nasopharyngeal carriage.

Roca A, Bottomley C, Hill PC, Bojang A, Egere U, Antonio M, Darboe O, Greenwood BM, Adegbola RA.

2012-06-1443 citations

10.1093/cid/cis554

Interventions

All young children who enter the trial will receive three doses of pneumococcal conjugate vaccine given at ages 2, 3 and 4 months through the Expanded Programme on Immunisation (EPI) programme. Infant

those living in group two villages will receive a single dose of control vaccine.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Resident of one of 21 Gambian villages

Exclusion criteria

Exclusion criteria: 1. Failure of the family/subject to give consent 2. Non-residence in the villages 3. Declared intent of the family/subject to leave the study area permanently within the following three months 4. Previous exposure to a conjugate pneumococcal vaccine

Design outcomes

Secondary

Measure	Time frame
1. Acquisition rates of nasopharyngeal carriage in newborns resident in vaccinated or control villages 2. Evidence for an increased rate of capsular switching in villages where community-wide pneumococcal conjugate vaccination has been introduced 3. Measurements of Immunoglobulin G (IgG) and Immunoglobulin A (IgA) levels in serum and saliva	—

Primary

Measure	Time frame
1. Differences in the prevalence of nasopharyngeal carriage of pneumococci of vaccine or of non-vaccine serotype in study villages after vaccination 2. Differences in the prevalence of carriage with serotype 1 and serotype 5 pneumococci will be of particular importance	—

Countries

Gambia

Outcome results

None listed